Business Context and Reporting Period
Company: Thermo Electron Corporation (now Thermo Fisher Scientific Inc.)
Filing Type: Form 10-K Annual Report
Reporting Period: Fiscal year ended January 2, 1999
Headquarters: Waltham, Massachusetts
The Company is a global leader in monitoring, analytical, and biomedical instrumentation, biomedical products, paper recycling equipment, and alternative-energy systems. Its strategy involves commercializing R&D, acquiring complementary businesses, and spinning out subsidiaries to sell minority interests to outside investors. As of March 19, 1999, the Company had 29 subsidiaries with minority equity interests sold (23 publicly traded, 6 privately held).
Key Financial Metrics
Note: Specific consolidated revenue, net income, and cash flow figures for the fiscal year are incorporated by reference from the 1998 Annual Report to Shareholders and are not explicitly stated in the provided text.
- Research & Development (R&D) Expenditures: $367.3 million for 1998 (up from $335.4 million in 1997 and $299.3 million in 1996).
- R&D Breakdown (1998): $154.2 million sponsored by customers; $213.2 million Company-sponsored.
- Order Backlog (Year-End 1998): $956.3 million (up from $895.5 million in 1997).
- Market Capitalization (Non-affiliates): Approximately $2.57 billion as of January 29, 1999.
- Shares Outstanding: 158,133,782 shares of Common Stock as of January 29, 1999.
- Employees: Approximately 23,600 as of January 2, 1999.
- Debt Instruments: Includes 4 1/4% Subordinated Convertible Debentures due 2003 and 7.625% Notes due 2008 ($150 million aggregate principal).
Material Changes and Segment Performance
Acquisitions and Divestitures:
- Spectra-Physics AB: Acquired in February 1999 for approximately $355 million. The target reported 1998 revenues of $442 million and specializes in laser-based instrumentation.
- Crusader Engines: Divested industrial and marine engine product lines in 1998 due to declining profitability to refocus on core traffic-control operations.
- ThermoLase Spas: Closed three U.S. and one overseas spa; repositioned remaining domestic spas under the "Greenhouse" name.
Backlog Analysis:
- Measurement and Detection: Decreased to $309.6 million (from $331.6 million) due to lower demand in Asia and a slowdown in the semiconductor industry.
- Biomedical and Emerging Technologies: Increased to $281.3 million (from $214.0 million).
- Energy and Environment: Increased to $288.1 million (from $274.7 million).
- Recycling and Resource Recovery: Increased to $77.3 million (from $75.2 million).
Outlook, Risks, and Management Commentary
Strategic Reorganization: The Company announced a proposed reorganization to consolidate businesses and reduce the number of majority-owned public subsidiaries from 23 to 16. This aims to improve management coordination and increase liquidity in public markets.
Leadership Changes: Richard F. Syron was appointed President and CEO effective June 1, 1999. George N. Hatsopoulos will become non-executive Chairman, and Arvin H. Smith will move to an advisory role.
Risks and Contingencies:
- Regulatory Approval: Thermo Cardiosystems' electric LVAS received FDA approval in September 1998 as a "bridge to transplant." Trex Medical's digital mammography application was withdrawn by the FDA in December 1998 but deemed active in January 1999 pending additional information.
- Supply Chain: Certain raw materials for the LVAS are available from only one or two suppliers, creating potential shortage risks.
- Seasonality: Thermo Ecotek earns a disproportionate share of income from May through October. Thermo Power's Peek subsidiary sees higher sales in Q2 and Q4.
- Competition: Highly competitive markets in biomedical devices (e.g., cardiac assist devices) and environmental services, with significant barriers to entry regarding FDA approval and government funding.
Investor Verification Checklist
- Verify the final terms and integration progress of the Spectra-Physics AB acquisition ($355 million cost).
- Confirm the status of the proposed corporate reorganization and its impact on the number of public subsidiaries.
- Monitor the FDA review process for Trex Medical's digital mammography system following the January 1999 reactivation of the application.
- Assess the impact of the semiconductor industry slowdown on the Measurement and Detection segment backlog.
- Review the full Consolidated Financial Statements in the 1998 Annual Report to Shareholders for specific revenue, profit, and cash flow figures not detailed in this 10-K text.